ZimVieNASDAQ: ZIMV

ZimVie Inc., a global leader in the dental market, has announced its participation in two upcoming investor conferences.

ZimVie Inc. (ZIMV) Q4 2023 Earnings Call Transcript

ZimVie's stock has doubled since reporting Q3 earnings, causing investors to wonder about the company's future. The company's Q3 revenues declined less than expected and the company raised full-year guidance. More importantly, ZimVie's decision to sell its spine business for $375 million jettisons an underperforming segment while solving a debt overhang.

ZimVie Inc. (NASDAQ:ZIMV ) Q3 2023 Earnings Conference Call November 1, 2023 4:30 PM ET Company Participants Marissa Bych - Investor Relations, Gilmartin Group LLC Vafa Jamali - President and Chief Executive Officer Richard Heppenstall - Chief Financial Officer Conference Call Participants Lilly Wyttenbach - JPMorgan Matt Miksic - Barclays Operator Good day, and thank you for standing by. Welcome to the ZimVie Third Quarter 2023 Financial Results Conference Call.

ZimVie's (ZIMV) Biotivity A/C Plus Membrane is a barrier membrane that contains an array of growth factors.

If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, ZimVie Inc. (ZIMV) could be a great choice. It is one of the several stocks that passed through our 'Fast-Paced Momentum at a Bargain' screen.

ZimVie Inc. (NASDAQ:ZIMV ) Q2 2023 Earnings Conference Call August 2, 2023 4:30 PM ET Company Participants Marissa Bych - Investor Relations, Gilmartin Group LLC Vafa Jamali - President and Chief Executive Officer Rich Heppenstall - Chief Financial Officer Conference Call Participants Robert Marcus - JPMorgan Chase & Co. Matt Miksic - Barclays Operator Good afternoon, and welcome to ZimVie's Second Quarter 2023 Earnings Conference Call. Currently, all participants are in listen-only mode.

ZimVie Inc. (ZIMV) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

ZimVie's stock price has increased by 19% since November, but the company's fundamentals have deteriorated significantly. The company's revenue guidance for 2023 is set at $848 million, a 6.7% decline from 2022, and LTM CFO has been cut in half from $55 million in Q3/22 to $27 million in Q1/23. With deteriorating fundamentals and higher valuations, I lower the rating on ZIMV to a hold and advise investors to wait for better valuations before considering a position in the company.